Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

07/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
30/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

07/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
30/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
22/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
22/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
09/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
06/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
06/03/15	Wall Street closes up slightly ahead of jobs report	RE
06/03/15	AbbVie : CEO says new form of Humira could thwart generics	RE
06/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
06/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

08/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
08/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
08/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

06/03/15	Wall Street se reprend un peu dans un climat d'attente
06/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
06/03/15	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
06/03/15	Début d'année en fanfare pour les fusions dans la pharmacie
06/03/15	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	01/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.21%	-7.67%	+61.07%	+71.32%	68.92B
ARGENX SE	+1.66%	+7.51%	+8.12%	+61.40%	51.9B
LONZA GROUP AG	+3.14%	+7.17%	+12.48%	+41.70%	48.73B
IQVIA HOLDINGS INC.	+3.28%	+4.47%	+33.15%	+35.92%	43.13B
REVOLUTION MEDICINES, INC.	-1.85%	+1.15%	+283.95%	+457.69%	41.48B
BEONE MEDICINES AG	+6.02%	+6.35%	+17.78%	+114.07%	39.96B
CELLTRION, INC.	+1.28%	-0.76%	+12.67%	+45.10%	30.6B
WUXI BIOLOGICS (CAYMAN) INC.	-2.21%	-14.22%	+40.33%	-0.94%	26.01B
BIONTECH SE	+2.01%	-2.03%	-13.56%	-6.99%	22.27B
Average	+1.49%	-3.90%	+50.67%	+91.03%	41.44B
Weighted average by Cap.	+1.55%	-3.49%	+54.40%	+97.66%